

## Alerts and Recalls

Generic Name (Trade Name—Company)

Uses/Notes

September 4, 2018

### **Multiple generic names**

**(*Neuroveen*, *Respitrol*, *Thyroveev*,  
*Compulsin*—HelloLife)**

**FDA alerts consumers of HelloLife's voluntary recall  
of Neuroveen, Respitrol, Thyroveev, and Compulsin**

HelloLife is initiating a voluntary recall of four different products, Neuroveen, Respitrol, Thyroveev, and Compulsin, within expiry, to the retail and consumer level because of possible microbial contamination. Neuroveen has been tested and found to be contaminated with *Staphylococcus saprophyticus* and *Burkholderia cepacia*. Compulsin has been identified as containing *Burkholderia cepacia*.

Respitrol and Thyroveev are still pending bacterial identification. Each product being recalled is for a single lot that was packaged into 2-ounce amber bottles (see table [here](#)) that were manufactured at the King Bio facility in Asheville, NC.

To date, HelloLife has not received any reports of adverse events related to the recalled products.

### **Source URL:**

<http://www.aphanet.org/alerts-and-recalls/fda-alerts-consumers-hellolife's-voluntary-recall-neuroveen-respitrol-thyroveev>  
v

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.